AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CRSP · NASDAQ · Biotechnology

CRISPR Therapeutics (CRSP)

Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.

$56.56

vs last close−2.47 (−4.18%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	200	1	1	1	35	1	1	1	1	1	10
Cost of revenue	23	20	52	57	16	0	58	50	65	59	50	45
Gross profit	−23	180	−51	−56	−15	35	−57	−49	−64	−59	−49	−34
	109	110	89	95	95	100	92	84	68	96	81	80
Research & development	91	95	71	75	77	82	72	65	59	78	69	65
	18	16	18	19	17	18	19	19	17	18	17	15
General & administrative	18	16	18	19	0	18	19	19	17	18	17	0
Other expenses	0	−1	0	0	0	−1	0	0	−8	0	−4	0
Operating income	−132	70	−141	−151	−110	−65	−148	−133	−132	−155	−130	−115
	21	20	25	26	25	28	14	−74	26	25	8	25
Other non-operating income	0	−20	−25	−26	−25	−28	−14	74	−26	−25	−8	0
Income before tax	−112	90	−116	−125	−85	−37	−135	−207	−106	−130	−122	−90
Income tax expense	0	0	1	1	1	1	1	1	1	1	1	1
Net income from continuing operations	−112	89	−117	−126	−86	−37	−136	−209	−106	−131	−123	−91
Net income	−112	89	−117	−126	−86	−37	−136	−209	−106	−131	−123	−91
EPS, basic	−$1.41	$1.12	−$1.43	−$1.49	−$1.01	−$0.44	−$1.58	−$2.40	−$1.17	−$1.37	−$1.28	−$0.94
EPS, diluted	−$1.41	$1.10	−$1.43	−$1.49	−$1.01	−$0.44	−$1.58	−$2.40	−$1.17	−$1.37	−$1.28	−$0.94
Weighted average shares, basic	79	80	82	85	85	85	86	87	91	90	96	97
Weighted average shares, diluted	79	81	82	85	85	85	86	87	91	90	96	97
EBITDA	−127	94	−111	−120	−80	−32	−130	−203	−101	−124	−118	−110
Depreciation & amortization	5	5	5	5	5	5	5	5	4	6	4	4
EBIT	−132	90	−116	−125	−85	−37	−135	−207	−106	−130	−122	−115